<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00714272</url>
  </required_header>
  <id_info>
    <org_study_id>KSGA0801</org_study_id>
    <secondary_id>F002MN0107_1</secondary_id>
    <nct_id>NCT00714272</nct_id>
  </id_info>
  <brief_title>Granulocytapheresis in Psoriasis</brief_title>
  <acronym>GRIP</acronym>
  <official_title>Therapeutic Effect of Granulocytapheresis in Psoriasis (GRIP-study)Using a Novel Cellulose-based Adsorber Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EXcorLab GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Membrana GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nikkiso Co. Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nikkiso Medical GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EXcorLab GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective, randomized, controlled, double-blinded, multicenter study,&#xD;
      granulocytapheresis using a novel cellulose-based adsorber will be compared to control sham&#xD;
      treatment (placebo). The effects on clinical symptoms and on some inflammatory parameters of&#xD;
      patients with moderate to severe plaque psoriasis will be evaluated over a 24-week period.&#xD;
&#xD;
      The primary end-point is a ≥75 percent improvement in PASI (Psoriasis Area and Severity&#xD;
      Index).&#xD;
&#xD;
      The study purpose is to demonstrate a beneficial therapeutic effect of granulocytapheresis&#xD;
      using the novel cellulose-based adsorber device in moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Primary outcome not achieved.&#xD;
  </why_stopped>
  <start_date type="Actual">February 18, 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>&gt;/=75 % Improvement in PASI (Psoriasis Area and Severity Index) on an Intention-to-treat Basis</measure>
    <time_frame>At the end of the granulocytapheresis treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving an Improvement of PASI by &gt;/= 50%</measure>
    <time_frame>From baseline to weeks 2, 6, 12 and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Granulocytapheresis treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham device treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1</intervention_name>
    <description>6 treatments. One per week during the first six consecutive weeks.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with a sham device, EXcorLab box 1.2</intervention_name>
    <description>6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe plaque psoriasis with a PASI &gt;/=10&#xD;
&#xD;
          -  Age &gt;/= 18 years&#xD;
&#xD;
          -  Negative pregnancy test in woman of childbearing age acceptable method of&#xD;
             contraception for both men and women&#xD;
&#xD;
          -  Written informed consent that can be withdrawn at any time or for any reason&#xD;
&#xD;
          -  Discontinuation of any systemic psoriasis treatment. Washout period of at least two&#xD;
             weeks for prior systemic medications&#xD;
&#xD;
          -  Only emollients for topical treatment&#xD;
&#xD;
          -  No vaccinations for at least 14 days prior to first treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other forms of psoriasis (e.g., guttate, pustular, erythrodermic, palmoplantar etc.)&#xD;
&#xD;
          -  History of ongoing uncontrolled bacterial, fungal or viral infection (including&#xD;
             opportunistic infections); HIV positivity&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Clinically relevant thrombocytopenia or bleeding disorders&#xD;
&#xD;
          -  WBC &lt;4.000 or &gt;12.000/µl&#xD;
&#xD;
          -  Malignancy within the last five years (exception: successfully treated basal cell&#xD;
             carcinoma or squamous cell carcinoma of the skin)&#xD;
&#xD;
          -  Severe cardiac disorders, stroke, pulmonary disease within the last year&#xD;
&#xD;
          -  Any medical condition that, in the judgment of the investigators, would jeopardize the&#xD;
             patient's safety during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael P Schoen, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Goettingen, Department of Dermatology and Venerology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Wanner, Prof.Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Wuerzburg, Department of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva B Broecker, Prof.Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Wuerzburg, Department of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerhard A Mueller, Prof.Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University of Goettingen, Department of Nephrology and Rheumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Detlef Krieter, Dr.med.</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Wuerzburg, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Würzburg, Department of Medicine, Division of Nephrology, and Department of Dermatology</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bavaria</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Göttingen, Department of Dermatology and Department of Nephrology and Rheumatology</name>
      <address>
        <city>Göttingen</city>
        <state>Lower Saxony</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>July 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2008</study_first_posted>
  <results_first_submitted>July 30, 2020</results_first_submitted>
  <results_first_submitted_qc>July 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2020</results_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>granulocytapheresis, psoriasis, PASI, apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A - Verum, Granulocytapheresis</title>
          <description>Granulocytapheresis treatment&#xD;
Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1: 6 treatments. One per week during the first six consecutive weeks.</description>
        </group>
        <group group_id="P2">
          <title>B - Control, Sham Treatment</title>
          <description>Sham device treatment&#xD;
Treatment with a sham device, EXcorLab box 1.2: 6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A - Verum, Granulocytapheresis</title>
          <description>Granulocytapheresis treatment&#xD;
Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1: 6 treatments. One per week during the first six consecutive weeks.</description>
        </group>
        <group group_id="B2">
          <title>B - Control, Sham Treatment</title>
          <description>Sham device treatment&#xD;
Treatment with a sham device, EXcorLab box 1.2: 6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" lower_limit="28" upper_limit="63"/>
                    <measurement group_id="B2" value="49.5" lower_limit="43" upper_limit="56"/>
                    <measurement group_id="B3" value="45" lower_limit="28" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>&gt;/=75 % Improvement in PASI (Psoriasis Area and Severity Index) on an Intention-to-treat Basis</title>
        <time_frame>At the end of the granulocytapheresis treatment period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Verum, Granulocytapheresis</title>
            <description>Granulocytapheresis treatment&#xD;
Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1: 6 treatments. One per week during the first six consecutive weeks.</description>
          </group>
          <group group_id="O2">
            <title>B - Control, Sham Treatment</title>
            <description>Sham device treatment&#xD;
Treatment with a sham device, EXcorLab box 1.2: 6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>&gt;/=75 % Improvement in PASI (Psoriasis Area and Severity Index) on an Intention-to-treat Basis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving an Improvement of PASI by &gt;/= 50%</title>
        <time_frame>From baseline to weeks 2, 6, 12 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A - Verum, Granulocytapheresis</title>
            <description>Granulocytapheresis treatment&#xD;
Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1: 6 treatments. One per week during the first six consecutive weeks.</description>
          </group>
          <group group_id="O2">
            <title>B - Control, Sham Treatment</title>
            <description>Sham device treatment&#xD;
Treatment with a sham device, EXcorLab box 1.2: 6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving an Improvement of PASI by &gt;/= 50%</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A - Verum, Granulocytapheresis</title>
          <description>Granulocytapheresis treatment&#xD;
Treatment with a Granulocyte Adsorber, Medica Adsorber 1.1: 6 treatments. One per week during the first six consecutive weeks.</description>
        </group>
        <group group_id="E2">
          <title>B - Control, Sham Treatment</title>
          <description>Sham device treatment&#xD;
Treatment with a sham device, EXcorLab box 1.2: 6 sham treatments. One treatment per week during the first six consecutive weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was discontinued after only 4 patients because of unforeseen exit of PI from the study location.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Horst-Dieter Lemke</name_or_title>
      <organization>eXcorLab GmbH</organization>
      <phone>+49-6022-812648</phone>
      <email>horstdieter.lemke@excorlab.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

